Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone
This trial is active, not recruiting.
|Condition||type 2 diabetes mellitus|
|Sponsor||Albert Einstein College of Medicine of Yeshiva University|
|Trial identifier||NCT00179400, 2000-200|
Doctors are studying natural oils as potential therapies for type 2 diabetes. Animal studies have suggested promising results using EPA (found in fish oils) to improve insulin action and lower blood sugar levels.
|Endpoint classification||pharmacodynamics study|
|Intervention model||single group assignment|
Male or female participants from 18 years up to 65 years old.
Inclusion Criteria: Type 2 subjects with an A1c over 8.% Exclusion Criteria: Those with bleeding disorders including GERD, PUD, any GI bleeding; High blood pressure, and anyone with a history of Coronary Artery Disease or exertional chest pain
|Official title||The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans|
|Principal investigator||Meredith Hawkins, MD|
|Description||PARTICIPATION INCLUDES: Participation in the studies includes taking study capsules for up to 21 days, keeping a meal diary, and up to four overnight hospital stays. During the hospital visits, an IV will be placed in each arm, and small amounts of muscle and fat tissue will be removed (with minimal discomfort). COMPENSATION: Compensation of $400 per study is provided (or up to $1,600 for completing all studies)|
Call for more information